Calando Says Strength of Phase I Trial of CALAA-01 Will Attract Partners, Including Suitors
May 20, 2010
Calando Says Strength of Phase I Trial of CALAA-01 Will Attract Partners, Including Suitors
Although in the short term it will continue to focus on CALAA-01, the siRNA-based drug expected to create partnerships for Calando, Arrowhead is considering initiating new drug-development programs.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Arrowhead Names HBV as Next RNAi Program While It Consolidates Operations
February 16, 2012 / Gene Silencing News - Arrowhead to Move Calando Cancer Drug into Phase Ib, Reports Fiscal Q3 Results
August 11, 2011 / Gene Silencing News - Calando, CalTech Researchers Publish Phase I Data on siRNA Cancer Drug
March 25, 2010 / Gene Silencing News - Tekmira Releases Phase I Cancer Drug Data, Plans Phase II Trial in Neuroendocrine Tumors
April 11, 2013 / Gene Silencing News - Silence Plans $28.6M Stock Sale to Fund Expansion of Staff, Pipeline
April 11, 2013 / Gene Silencing News